The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibitors (ICI) in thymic epithelial tumors (TET): A real world assessment of efficacy and toxicity.
 
Guilherme Sacchi de Camargo Correia
No Relationships to Disclose
 
Reema Tawfiq
No Relationships to Disclose
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Yujie Zhao
Employment - Mayo Clinic
Research Funding - Alpine Immune Sciences (Inst); AstraZeneca (Inst); Elucida Oncology (Inst); GI Innovation Inc (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Seagen (Inst); SparX Biotech; Zai Lab (Inst)
 
Shenduo Li
No Relationships to Disclose
 
Vinicius Ernani
Consulting or Advisory Role - AstraZeneca/MedImmune; BioAtla; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novocure; Nuvation Bio
Research Funding - AstraZeneca/MedImmune
 
Kaushal Parikh
Consulting or Advisory Role - AstraZeneca (Inst); MJH Life Sciences; Takeda Science Foundation (Inst)
 
Rami Manochakian
Consulting or Advisory Role - Abbvie; Alpha 2; AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Daiichi Sankyo inc; Guardant Health; Janssen; Novocure; Oncohost; Takeda; Turning Point Therapeutics